ACAlicia Cerretani

Alicia Cerretani

*This is an algorithmically generated author record based on publicly available information.

Alicia Cerretani has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study

    by Aaron T Gerds, Qi Fan, Michelle Jerry, Alicia Cerretani, Anh Thu Tran, Luis Hernandez

    Purpose: To evaluate treatment and disease burden among patients with polycythemia vera (PV) receiving the current standard of care (SoC) in the US. Patients and Methods: This retrospective study utilized MarketScan® Commercial/Medicare Databases to identify patients with PV diagnosis and treatment claims between 1/1/2011-12/31/2022 (index date=earliest PV treatment date), continuous enrollment (6 months pre-index and ≥ 12 months post-index), and no pre-index disease progression (myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome). Patients were categorized by thrombosis risk (high/low-risk) and 12-month post-index treatments: phlebotomy (PHL) only, hydroxyurea (HU) only, PHL+HU, or ruxolitinib/interferons (RUX/IFN). Outcomes included incident TE, iron deficiency anemia, disease progression, and PV-related symptoms. Hematocrit (HCT) control was evaluated in patients with ≥ 2 HCTs post-index (HCT analysis). All-cause costs during the 12 months post-TE were reported in patients with an incident TE and ≥ 12 months post-TE follow-up (TE analysis). Results: Among 11,311 patients (51.8% high-risk; 48.2% low-risk; median follow-up ~2.8 years), 12-month post-index treatments included PHL only (75.0%), HU only (12.2%), PHL+HU (10.9%), and RUX/IFN (1.9%). Frequent PHL (≥ 3 PHL in 6 months or ≥ 5 PHL in 12 months post-index; 46.2% of PHL users) and high-dose HU (≥ 1000mg/day; 41.7% of HU users) were common. Within 12 months post-index, 50.9% of patients experienced burdensome treatment (frequent PHL, high-dose HU) and/or an incident TE. During the full follow-up, 15.3% experienced incident TE, 9.6% experienced incident iron deficiency anemia, 4.4% experienced disease progression, and 83.2% experienced symptoms. For the HCT analysis (N=1,268), 85.3% had uncontrolled HCTs≥ 45%, with 55.4% having HCTs≥ 50%. For the TE analysis (N=1,159), mean 12-month all-cause costs post-TE were $71,195, with 29.2% attributable to the index TE. Conclusion: Patients with PV have high treatment and disease burden with the current SoC. Current PV therapies (PHL, cytoreductive agents) do not consistently maintain HCT< 45%, leaving patients at increased risk for life-threatening and costly TEs.


  • Open Access

    Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis

    by Caitlin Montcrieff, Jorge Caicedo, Alicia Cerretani, Angela (Qi) Fan, Michael Bullano, Ekaterina Ponomareva

    Emicizumab has changed prophylactic treatment for HA, but the need for FVIII replacement still exists for the treatment of breakthrough bleeds, perioperative management, and participation in high-risk activities/sports. The primary objectives of this study were to describe the characteristics of individuals with congenital hemophilia A (HA) without inhibitors receiving emicizumab prophylaxis and to compare clinical outcomes, healthcare resource utilization (HCRU), and costs among those prescribed octocog alfa [Advate, standard half-life factor VIII (FVIII)] versus extended half-life (EHL) FVIII agents. Patients with congenital HA without inhibitors and emicizumab use were identified retrospectively from Inovalon claims data and stratified by concomitant octocog alfa vs. EHL FVIII use. Inverse probability treatment weighting (IPTW) and multivariable regression were used to balance baseline covariates and compare billable annualized rate of bleeding (ABRb), healthcare utilization, and costs between subgroups. Among the 1,282 patients receiving emicizumab prophylaxis, 501 received concomitant FVIII prescription for octocog alfa (n = 274) or EHL (n = 227) during follow-up. Following IPTW adjustment, total and medical costs were comparable between groups; however, pharmacy costs associated with concomitant octocog alfa therapy were significantly lower compared with EHL products ($35,381 vs. $61,739; p < 0.001). Importantly, ABRb (0.35 vs. 0.28; p = 0.34) and bleed-related healthcare utilization remained similar across cohorts. Findings are limited by the retrospective design and reliance on claims data, which may omit home-treated bleeds, and misrepresent FVIII utilization due to billing complexities and assumptions about dispensed product use. While the choice of concomitant FVIII does not substantially influence ABRb or bleed-related HCRU, significantly lower pharmacy costs with octocog alfa compared with EHL agents highlight its potential cost saving and support its consideration as a preferred on-demand treatment option in patients with HA without inhibitors on emicizumab prophylaxis.